Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N05 PSYCHOLEPTICS
N05A ANTIPSYCHOTICS
N05AX Other antipsychotics
N05AX12 Aripiprazole
D01164 Aripiprazole (JP18/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Antidepressants
Antidepressants, Other
Aripiprazole
D01164 Aripiprazole (JP18/USP/INN)
Antipsychotics
2nd Generation/Atypical
Aripiprazole
D01164 Aripiprazole (JP18/USP/INN)
Bipolar Agents
Bipolar Agents, Other
Aripiprazole
D01164 Aripiprazole (JP18/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
117 Psychotropics
1179 Others
D01164 Aripiprazole (JP18/USP/INN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG03200 Antipsychotic agent
DG03064 Atypical antipsychotic
DG00906 Aripiprazole
D01164 Aripiprazole
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG00906 Aripiprazole
D01164 Aripiprazole
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00906 Aripiprazole
D01164 Aripiprazole
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Dopamine
DRD2
D01164 Aripiprazole (JP18/USP/INN) <JP/US>
DRD3
D01164 Aripiprazole (JP18/USP/INN) <JP/US>
Serotonin
HTR1A
D01164 Aripiprazole (JP18/USP/INN) <JP/US>
HTR2A
D01164 Aripiprazole (JP18/USP/INN) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D01164 Aripiprazole
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D01164
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D01164
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D01164
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D01164
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D01164
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D01164
Prodrugs [br08324.html]
D01164
Drug groups [BR:br08330]
Neuropsychiatric agent
DG03200 Antipsychotic agent
DG03064 Atypical antipsychotic
DG00906 Aripiprazole
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG00906 Aripiprazole
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00906 Aripiprazole